Ignite Creation Date:
2024-05-06 @ 5:37 PM
Last Modification Date:
2024-10-26 @ 2:32 PM
Study NCT ID:
NCT05378321
Status:
RECRUITING
Last Update Posted:
2024-03-01
First Post:
2022-04-13
Brief Title:
Prevalence of NAFLD in ACS Patients
Sponsor:
Ziekenhuis Oost-Limburg
Organization:
Ziekenhuis Oost-Limburg
Study Overview
Official Title:
The Prevalence of Non-Alcoholic Fatty Liver Disease in Patients With an Acute Cardiac Event Followed at Ziekenhuis Oost-Limburg Genk Belgium
Status:
RECRUITING
Status Verified Date:
2024-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
PADAC
Brief Summary:
Addressing CVD risk in patients with NAFLD is the aspect of the disease most amenable to medical management and so improving long-term clinical outcomes Almost no studies have been done concerning the prevalence of NAFLD in CVD patients most of the conducted studies have been done in already diagnosed NAFLD patients to estimate the risk of CVD development Currently there are no data available about the prevalence of NAFLD in CVD more specifically patients with an acute cardiovascular event ACE in Belgium
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None